| In vivo imaging of cancer biomarkers using activatable molecular probes. | |
| | |
MedLine Citation:
|
PMID: 19126958 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
With the continued advancements in cellular and molecular biology, especially in the areas of genomics, proteomics and metabolomics, the scientific research community is gaining ground in uncovering the tortuous details associated with cancer. Molecular imaging has undergone a similar progression and is showing promise as a future method to aid in the early detection of malignancies, locating metastatic disease, staging tumors, evaluating the availability of therapeutic targets, and monitoring the efficacy of treatment. A subset of molecular imaging contrast agents known as "activatable molecular probes" has generated a particularly high level of excitement in the imaging community. Activatable molecular probes are designed to elicit a detectable change in signal upon enzymatic activity or in response to specific biomolecular interactions. In many cases, these unique characteristics allow for very high signal-to-background ratios compared with conventional targeted contrast agents and they open up the possibility of imaging intracellular targets. In this review, we will discuss some of the activatable probes recently developed for optical and magnetic resonance imaging platforms and their use in the visualization of cancer biomarkers in vivo. |
| | |
Authors:
|
Drew R Elias; Daniel L J Thorek; Antony K Chen; Julie Czupryna; Andrew Tsourkas |
Related Documents
:
|
9915668 - The use of laser doppler imaging as an aid in clinical management decision making in th... 7881888 - Technical note: low density contrast in upper abdominal computed tomography. 3259368 - Ct of the pancreas with a fat-density oral contrast regimen. 19902338 - Liquid perfluorocarbons as contrast agents for ultrasonography and (19)f-mri. 7710998 - Correlation between left frontal phospholipids and wisconsin card sort test performance... 9915668 - The use of laser doppler imaging as an aid in clinical management decision making in th... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Cancer biomarkers : section A of Disease markers Volume: 4 ISSN: 1574-0153 ISO Abbreviation: - Publication Date: 2008 |
Date Detail:
|
Created Date: 2009-01-07 Completed Date: 2009-03-10 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101256509 Medline TA: Cancer Biomark Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 287-305 Citation Subset: IM |
Affiliation:
|
Cellular and Molecular Imaging Group, Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Diagnostic Imaging* Humans Magnetic Resonance Imaging / methods Molecular Probe Techniques* Neoplasms / diagnosis* Tumor Markers, Biological* |
| Chemical | |
Reg. No./Substance:
|
0/Tumor Markers, Biological |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Heparin induced thrombocytopenia management with bivalirudin.
Next Document: Quantum dot bioconjugates for in vitro diagnostics & in vivo imaging.